Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth

Investors

Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

Historical & comparative data

Change in reporting of the Animal Health Business

Sales and Business net income statements for each quarter of 2015 and the first three quarters of 2016 with Animal Health Business reported on a separate line “Business net income of Animal Health Business”:

 

Sales of Global Business Units

From Q1 2016, Sanofi will report sales of Global Business Units (GBU) - Diabetes & Cardiovascular, General Medicines & Emerging Markets, Sanofi Genzyme (Specialty Care), Sanofi Pasteur (Vaccines) and Merial (Animal Health) - and use a new geographic split.

Below are historical sales of GBUs by geographic region and product.

 

Change in presentation of VaxServe

VaxServe sales of non-Sanofi products are reported on the line Other revenues in the income statement from January 1, 2016. Accordingly, prior period comparative net sales have been reclassified to the line Other revenues.

In order to ensure the comparability of Sanofi’s Global Franchises, Aggregate Company Sales and Aggregate Other Revenues, please find below:

 

IFRIC 21

New interpretation of tax levies - applicable as from January 1st, 2014.

 

IAS19R

Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013.

 

Adoption of Business Net Income

Sanofi adopted "Business Net Income" in Q1 2010, a Non-Gaap indicator in connection to the application of IFRS 8.

 

Right area:

Stock Market

Regeneron Alliance

 

IR mobile application

SANOFI IR - The Investor Relations Mobile Application

SANOFI IR is available on iPhone, iPad, Apple Watch and Android!
NEW - Section dedicated to Individual Shareholders

 
 

© Sanofi 2004-2017 - All rights reserved - Update: January 23, 2017

  • Site complies with W3C WCAG 2.0 (new window, in english)